Course Detail

This online module will discuss oral and injectable medications to treat diabetes including combination regimens. The learner will consider the American Diabetes Association (ADA) guidelines and the therapeutic experiment as they practice the pharmacotherapeutic management of patients with diabetes and cardiovascular disease (CVD).

Learning Objectives:
At the end of this activity, participants should be able to:

1. State the general approaches to treatment recommended by the American Diabetes Association (ADA) and American Association of Clinical Endocrinologist (AACE);
2. Describe the mechanism of action, advantages, major adverse effects, and relative cost of the following medication classes: Alpha-glucosidase inhibitor, Amylin analogs, Biguanides, Bile acid sequestrants, Dipeptidyl-peptidase-4 (DPP4) inhibitors, Dopamine agonists, Glucagon-like peptide-1 (GLP-1) receptor agonists, Insulin – human and insulin analogs, Meglitinides, Sodium glucose transporter-2 (SGLT2) inhibitors, Sulfonylureas and Thiazolidenediones (TZDs);
3. Explain why metformin is the cornerstone of therapy for type 2 diabetes;
4. Given a brief case vignette, determine what patient-related variables should influence the treatment recommendation and what additional information is needed to make a well-informed decision;
5. Given a brief case vignette, develop a patient monitoring plan including indices of efficacy and toxicity; and
6. Given a brief case vignette, develop a patient education plan.

CE: 3.5 Contact Hours
Universal Activity Number (UAN): 0025-0000-16-057-H01-P
Expiration Date: 5/1/2019
Course Number: Ke-CN#ENDO002
Instructor: Stuart T. Haines, PharmD, BCPS, BACP, BC-ADM, Professor, Department of Pharmacy Practice and Science, University of Maryland School of Pharmacy

Click here for additional course details.